Breast cancer - Response rates to chemotherapeutic agents studied in vitro

Anticancer Research

Volumn 23, Issue 4, 2003, Pages 3405-3411

  Kornblith, Paul ^a   Wells, Alan ^b   Gabrin, Michael J ^a   Piwowar, John ^a   George, Lisa D ^a   Ochs, Robert L ^a   Burholt, Dennis ^a  

^a Precision Therapeutics Inc   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Chemoresponse; Patterns of response

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; PACLITAXEL;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; FLUOROURACIL; HUMANS; PACLITAXEL; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 0041527257     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Ochs RL, Fensterer J, Ohori NP et al: Evidence for the isolation, growth, and characterization of malignant cells in primary cultures of human tumors. In Vitro Cellular and Developmental Biology-Animal 39(5), 2003. In Press.
2. Ness RB, Wisniewski SR, Eng H et al: Cell viability assay for drug testing in ovarian cancer: in vitro kill versus clinical response. Anticancer Res 22: 1145-1149, 2002.
3. Kornblith P, Wells A, Gabrin MJ et al: In vitro responses of ovarian cancers to platinums and taxanes. Anticancer Res 23: 543-548, 2003.
4. Sledge GW, Neuberg D, Bernardo P et al: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21: 588-592, 2003.
5. Zambetti M, Terenziani M, Bartoli C et al: Intermediate doses of cyclophosphamide alone or following adriamycin in advanced breast cancer. A pilot study. Am J Clin Oncol 19: 82-86, 1996.
6. Mouridsen HT, Palshof T, Brahm M et al: Evaluation of single-drug versus multiple-drug chemotherapy in the treatment of advanced breast cancer. Cancer Treat Rep 61: 47-50, 1977.
7. Rubens RD, Knight RK and Hayward JL: Chemotherapy of advanced breast cancer: a controlled randomized trial of cyclophosphamide versus a four-drug combination. Br J Cancer 32: 730-736, 1975.
8. Gordon F and McArthur J: Thiotepa and cyclophosphamide in the treatment of advanced mammary cancer. Scot Med J 10: 27-33, 1965.
9. Talley RW, Vaitkevicius VK and Leighton GA: Comparison of cyclophosphamide and 5-fluorouracil in the treatment of patients with metastatic breast cancer. Clin Pharmacol Ther 6: 740-748, 1965.
10. Foley JF: Effect of cyclophosphamide (NSC-2627) on far-advanced neoplasia. Cancer Chemother Rep 34: 55-58, 1964.
11. Gold GL: Shnider BI, Salvin LG, Schneiderman MA, Colsky J, Owens AH Jr, Krant MJ, Miller SP, Frei E 3d, Hall TC, Spurr CL, McIntyre OR, Hoogstraten B and Holland JF: The use of mechlorethamine, cyclophosphamide, and uracil mustard in neoplastic disease: a cooperative study. J Clin Pharmacol J New Drugs 10: 110-120, 1970.
12. Bramwell VH, Howell A, Anderson H et al: Intermediate dose single agent cyclophosphamide chemotherapy of advanced breast cancer. Clin Oncol 9: 251-256, 1983.
13. Piro AJ, Wilson RE and Nevinny HB: Cyclophosphamide therapy in patients with advancing breast cancer following adrenalectomy and 5-fluorouracil. Cancer 27: 1342-1345, 1971.
14. Hansen F, Moller P and Skovsgaard T: Phase II study of second-line treatment with high-dose cyclophosphamide in recurrent metastatic breast cancer. Cancer Chemother Pharmacol 37: 377-381, 1996.
15. Coggins PR, Ravdin RG and Eisman SH: Clinical evaluation of a new alklating agent: Cytoxan (cyclophosphamide). Cancer 13: 1254-1260, 1960.
16. Bergsagel DE and Levin WC: A preclusive clinical trial of cyclophosphamide. Cancer Chemother Rep 7: 120-134, 1960.
17. Rundles RW, Laszlo J, Garrison FE et al: The antitumor spectrum of cyclophosphamide. Cancer Chemother Rep 16: 407-411, 1962.
18. Bergsagel DE, Robertson GL and Hasselback R: Effect of cyclophosphamide on advanced lung cancer and the hematological toxicity of large, intermittent intravenous doses. Can Med Assoc J 98: 532-538, 1968.
19. Gradishar WJ: Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer. Oncology (Huntingt) 11: 15-18, 1997.
20. Chevallier B, Fumoleau P, Kerbrat P et al: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13: 314-322, 1995.
21. Fumoleau P, Chevallier B, Kerbrat P et al: A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann Oncol 7: 165-171, 1996.
22. Hudis CA, Seidman AD, Crown JP et al: Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 14: 58-65, 1996.
23. Aihara T, Kim Y, Takatsuka and Y: Phase II study of weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 13: 286-292, 2002.
24. Borisova TA, Orel NF, Pirogova NA et al: Phase II study of Taxotere in advanced or/and metastatic breast cancer as a first or second line of treatment. Annals of Oncology, 1998, pp 28.
25. Ravdin PM: Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer. Semin Oncol 24: S10-18-S10-21, 1997.
26. Trudeau ME, Eisenhauer EA, Higgins BP et al: Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada- Clinical Trials Group. J Clin Oncol 14: 422-428, 1996.
27. Dieras V, Marty M, Tubiana N et al: Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer. Semin Oncol 22: 33-39, 1995.
28. Stemmler HJ, Gutschow K, Sommer H et al: Weekly docetaxel (Taxotere) in patients with metastatic breast cancer. Ann Oncol 12: 1393-1398, 2001.
29. Jones RB, Holland JF, Bhardwaj S et at: A phase I-II study of intensive-dose adriamycin for advanced breast cancer. J Clin Oncol 5: 172-177, 1987.
30. Carmo-Pereira J, Costa FO, Henriques E et al: comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer 56: 471-473, 1987.
31. Perez DJ, Harvey VJ, Robinson BA et al: A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol 9: 2148-2152, 1991.
32. Hoogstraten B, George SL, Samal B et al: Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study. Cancer 38: 13-20, 1976.
33. Gundersen S, Kvinnsland S, Klepp O et al: Weekly adriamycin vs. 4-epidoxorubicin every second week in advanced breast cancer. A randomized trial. The Norwegian Breast Cancer Group. Eur J Cancer 26: 45-48,1990.
34. Brambilla C, Rossi A, Bonfante V et al: Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep 70: 261-266, 1986.
35. Gasparini G, Dal Fior S, Panizzoni GA et al: Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial. Am J Clin Oncol 14: 38-44, 1991.
36. Nylen U, Baral E, Svane G et al: Weekly doxorubicin in the treatment of metastatic breast carcinoma. Acta Oncol 28: 515-517, 1989.
37. Harris L, Batist G, Belt R et al: Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94: 25-36, 2002.
38. Paridaens R, Biganzoli L, Bruning P et al: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 18: 724-733, 2000.
39. Ivy HK: Treatment of breast cancer with 5-fluorouracil. Ann Intern Med 57: 598-605, 1962.
40. Hall BE and Good JW: Treatment of far-advanced cancer with 5-fluorouracil, used alone and in combination with irradiation. Incidence and duration of remission and survival-time data in 233 patients. Cancer Chemother Rep 16: 369-386, 1962.
41. Mackman S, Ramirez G and Ansfield FJ: Results of 5-fluorouracil (NSC-19893) given by the multiple daily dose method in disseminated breast cancer. Cancer Chemother Rep 51: 483-489, 1967.
42. Firat D and Olshin S: Treatment of metastatic carcinoma of the female breast with combination of hormones and other chemotherapy. Cancer Chemother Rep 52: 743-750, 1968.
43. Chu L, Sutton LM, Peterson BL et al: at-. Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer. J Infus Chemother 6: 211-216, 1996.
44. Van Way CW 3rd and Reynolds VH: A new method for treatment of carcinoma of the breast and colon with 5-fluorouracil. Am Surg 36: 210-218, 1970.
45. Crivellari D, Magri MD, Buonadonna A et al: Continuous infusion fluorouracil in the management of advanced breast cancer: a phase II study. Tumori 86: 42-45, 2000.
46. Klaassen U, Wilke H and Seeber S: Weekly high-dose infusional 5- fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin. J Infus Chemother 6: 127-132, 1996.
47. Regazzoni S, Pesce G, Marini G et al: Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer. Ann Oncol 7: 807-813, 1996.
48. Johnson EC, Ansfield FJ, Ramirez G et al: Further clinical studies of 5-fluorouracil (5-FU; NSC-19893) given by the multiple daily dose method in disseminated breast cancer. Cancer Chemother Rep 57: 59-63, 1973.
49. Chang AY, Most C and Pandya KJ: Continuous intravenous infusion of 5-fluorouracil in the treatment of refractory breast cancer. Am J Clin Oncol 12: 453-455, 1989.
50. Karapetis CS, Patterson WK, Pittman KB et al: Treatment of metastatic breast cancer with continuous infusional 5 fluorouracil. Aust N Z J Med 29: 517-522, 1999.
51. Chlebowski RT, Pugh RP, Weiner JM et al: Treatment of advanced breast carcinoma with 5-fluorouracil: a randomized comparison of two routes of delivery. Cancer 48: 1711-1714, 1981.
52. Ahmann DL, Bisel HF and Hahn RG: An evaluation of 5-fluorouracil in the treatment of advanced breast cancer. Mayo Clin Proc 42: 193-199, 1967.
53. Olson KB and Greene JR: Evaluation of 5-fluorouracil in the treatment of cancer. J Nat Cancer Inst 25;: 133-140, 1960.
54. Field JB: 5-fluorouracil (NSC-19893) treatment of advanced cancer in ambulatory patients. Cancer Chemother Rep 33: 45-49, 1963.
55. Moore GE, Bross ID, Ausmans R et al: Effects of 5-fluorouracil (NSC-19893) in 389 patients with cancer. Eastern Clinical Drug Evaluation Program. Cancer Chemother Rep 52: 641-653, 1968.
56. Ansfield FJ, Schroeder JM and Curreri AR: Five year clinical experience with 5-fluorouracil. JAMA 181: 295-299, 1962.
57. (ECOG) ECGiSTC: Comparison of antimetabolites in the treatment of breast and colon cancer. JAMA 200: 110-118, 1967.
58. Jacobs EM, Luce JK and Wood DA: Treatment of cancer with weekly intravenous 5-fluorouracil Cancer 22: 1233-1238, 1968.
59. Ansfield F, Klotz J, Nealon T et al: A phase III study comparing the clinical utility of four regimens of 5- fluorouracil: a preliminary report. Cancer 39: 34-40, 1977.
60. Carmichael J and Walling J: Advanced breast cancer: investigational role of gemcitabine. Eur J Cancer 33 Suppl 1: S27-30, 1997.
61. Luftner D, Flath B, Akrivakis C et al: Gemcitabine for palliative treatment in metastatic breast cancer. J Cancer Res Clin Oncol 124: 527-531, 1998.
62. Blackstein M, Vogel CL, Ambinder R et al at: Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 62: 2-8, 2002.
63. Possinger K, Kaufmann M, Coleman R et al: Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 10: 155-162, 1999.
64. Spielmann M, Llombart-Cussac A, Kalla S et al: Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 60: 303-307, 2001.
65. Buzdar AU, Singletary SE, Theriault RL et al: Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer., J Clin Oncol 17:3412-3417, 1999.
66. Swain SM, Honig SF, Tefft MC et al: A phase II trial of paclitaxel (Taxol) as first line treatment in advanced breast cancer. Invest New Drugs 13: 217-222, 1995.
67. Holmes FA, Walters RS, Theriault RL et al: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805, 1991.
68. Reichman BS, Seidman AD, Crown JP et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11: 1943-1951, 1993.
69. Davidson NG, Chick JB, Perren TJ et at: A phase II study of single agent paclitaxel in patients at first relapse following initial chemotherapy for breast cancer. Clin Oncol 8: 358-362, 1996.
70. Bishop JF, Dewar J, Toner G et al: A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5 fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand. Semin Oncol 24: S17-15-S17-19, 1997.
71. Perez EA, Vogel CL, Irwin DH et al: Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19: 4216-4223, 2001.
72. Nabholtz JM, Gelmon K, Bontenbal M et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14: 1858-1867, 1996.
73. Fisher B, Bryant J, Wolmark N et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685, 1998.
74. Batist G, Ramakrishnan G, Rao CS et al: Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19: 1444-1454, 2001.
75. Biganzoli L, Cufer T, Bruning P et al: Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol 20: 3114-3121, 2002.